GeneReach Biotechnology announced consolidated revenue of NT$17.31 million for June 2025, a 3.26% month-on-month decrease but a 65.54% increase compared to the same period last year. The company’s cumulative revenue for the first half of the year reached NT$107 million, representing a 20.10% year-on-year growth. GeneReach stated that in the second half of the year, it will further strengthen its global market presence, deepen penetration in existing markets, and continue to explore emerging market potential in South America, focusing on Ecuador and Paraguay, aiming to inject steady operational momentum.

GeneReach highlighted its breakthrough PCR nucleic acid detection technology platform as the foundation for its outstanding global market performance. The livestock industry chain has benefited from a surge in demand for rapid testing of swine fever and avian influenza. The Southeast Asian market remains highly active, with new regional distributors demonstrating strong execution capabilities, leading to a 73% increase in swine disease testing and a 30% increase in avian disease testing. In the companion animal segment, the company has made strong advances in the Middle East, rapidly expanding its veterinary client base and achieving an overall business growth of 31% compared to the same period last year.

Looking ahead to the second half of 2025, GeneReach plans to continue enhancing its global market layout, deepen market penetration, and tap further into emerging South American markets, especially Ecuador and Paraguay, to sustain solid growth momentum. To boost brand competitiveness, GeneReach will participate in domestic and international professional conferences in July to deepen cooperation with global veterinary medical institutions, expand its international brand influence, and explore strategic partnerships.

For the future, GeneReach said it will continue to strengthen its One Health development strategy by integrating PCR nucleic acid detection with next-generation sequencing (NGS) technologies to build a comprehensive cross-species pathogen surveillance network. This will provide holistic testing solutions covering human, animal, and environmental health, further consolidating its leadership in molecular diagnostics and enhancing its innovative competitiveness in the global biotech market.

Resource: 雙引擎驅動挹注營運，瑞基6月營收年增66%